106
Participants
Start Date
May 11, 2016
Primary Completion Date
March 6, 2019
Study Completion Date
August 21, 2022
Durvalumab
Administered as an IV infusion (250 mL) over approximately 1 hour in duration
Lenalidomide
Administered orally
Rituximab
Administered by intravenous infusion
Ibrutinib
Administered orally
Bendamustine
Administered as a 30-minute intravenous infusion
Weill Cornell Medical College, New York
Institut Paoli Calmettes, Marseille
Local Institution - 005, Rochester
University of Rochester, Rochester
Jefferson Medical Oncology Associates, Philadelphia
IRCCS Humanitas Clinical Institute, Rozzano (milano)
IEO- Istituto Europeo di Oncologia, Milan
A.O. Ospedale Ca Granda - Niguarda, Milan
Centre Hospitalier, Dijon
Local Institution - 306, Brescia
Spedali Civili Di Brescia, Brescia
I.R.C.C.S. Policlinico San Matteo, Pavia
Emory University, Atlanta
Shands Cancer Center University of Florida, Gainesville
Hopital Haut Leveque, Pessac
Moffitt Cancer Center, Tampa
CHU Montpellier, Montpellier
Local Institution - 102, Montpellier
CHRU Rennes, Rennes
UKG Universitatsklinikum Gottingen, Göttingen
University of Bologna, Bologna
The Ohio State University, Columbus
Centre Hospitalier Universitaire de Nantes, Nantes
Local Institution - 105, Nantes
Universitatsklinikum Essen, Essen
Universitatsklinik Koln, Köln
Mayo Clinic, Rochester
Northwestern University Feinberg School of Medicine, Chicago
Washington University School of Medicine, St Louis
Universitatsklinikum des Saarlandes, Homburg-Saar
Centre Hospitalier Lyon-Sud, Pierre-Bénite
Local Institution - 103, Pierre-Bénite
University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City
Centre Henri Becquerel, Rouen
Houston Methodist Cancer Center, Houston
MD Anderson Cancer Center, Houston
University of Colorado Cancer Center, Aurora
Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania
Local Institution - 304, Napoli, Campania
Medizinische Klinik III Klinikum der Universität München-Großhadern, München
Banner MD Anderson Cancer Center, Gilbert
Pinnacle Oncology Hematology, Scottsdale
Centre Hospitalier Universitaire d'Avicennes, Bobigny
Hopital Henri Mondor, Créteil
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
MD Anderson Cancer Center, Houston
Local Institution - 602, Chuo-ku
National Cancer Center Hospital, Chūōku
Tokai University Hospital, Isehara City, Kanagawa
Aichi Cancer Center, Nagoya
VU Academic Medical Center, Amsterdam, Amsterdam
UMC Groningen, Groningen
Leids Universitair Medisch Centrum, Leiden
Erasmus Medical Center, Rotterdam
Local Institution - 501, Rotterdam
Local Institution - 402, Plymouth
Derriford Hospital, Plymouth
Local Institution - 407, Nottingham
St James University Hospital, Leeds
UCL Cancer Institute, London
Christie Hospital NHS Trust, Manchester
Local Institution - 404, Manchester
Nottingham University Hospitals NHS Trust, Nottingham
Local Institution - 406, Oxford
Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine, Oxford
Southampton University Hospitals NHS Trust, Southampton
Lead Sponsor
Celgene
INDUSTRY